查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1771622

美國病毒疫苗CDMO市場規模、佔有率、趨勢分析報告：按類型、服務、工作流程、最終用途、地區、細分市場預測，2025-2033年

U.S. Viral Vaccines CDMO Market Size, Share & Trends Analysis Report By Type (Attenuated Vaccine, Inactivated Vaccine, DNA Vaccines, Subunit Vaccines), By Service, By Workflow, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國病毒疫苗CDMO市場趨勢：

預計 2024 年美國病毒疫苗 CDMO 市場規模將達到 7.502 億美元，2025 年至 2033 年的複合年成長率為 14.94%。

成長的關鍵驅動力在於政府的強力資金支持、疫苗技術的進步以及對快速可擴展生產日益成長的需求。此外，隨著製藥公司擴大採用外包模式以降低成本並縮短工期，擁有一次性系統、脂質奈米顆粒製劑和填充服務等先進能力的CDMO（合約研發生產組織）的需求也日益旺盛。戰略夥伴關係、疫情防治目標以及CEPI等組織的支持正在進一步推動市場成長。

呼吸道融合細胞病毒(RSV)、流感和猴痘等病毒性疾病的流行正在加速美國病毒疫苗 CDMO 市場的需求。受疫情影響，RSV 在 2022 年大幅飆升，導致 6 個月以下嬰兒的住院人數較疫情前增加了七倍。同時，2025 年初，44 個州的流感檢測陽性率上升至 18.7%，導致住院人數和兒童死亡人數增加。同時，2022 年至 2023 年，美國猴痘病例數超過 34,700 例，需要接種超過 100 萬劑 JYNNEOS 疫苗。這些激增迫使公共衛生機構和疫苗開發商提高生產能力，從而透過 CDMO、製程開發和基礎設施升級進行簽約，進而支持美國市場的成長。

美國病毒疫苗 CDMO 產業的成長在很大程度上受到公共衛生緊急事件和對可擴展、快速疫苗生產日益成長的需求的推動。諸如「曲速行動」之類的計畫促進了政府與 CDMO 的夥伴關係，並已撥款超過 100 億美元用於擴大 COVID-19 和未來流行病的國內生產。對大流行防範的關注促成了透過 BARDA 等實體簽訂的長期契約，從而形成了穩定的 CDMO計劃管道。同時，製藥和生技公司擴大委託疫苗開發和生產外包給 CDMO，以減少前期投資、加快上市時間並管理複雜病毒平台的風險。外包還使公司能夠專注於核心研發活動，同時利用 CDMO 的監管專業知識和 GMP 基礎設施。這種策略轉變，在病毒傳播和多效價疫苗開發中尤為明顯，使美國的 CDMO 成為國家生物安全和公私防範的關鍵推動者，增強了長期市場成長機會。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場展望
    • 母市場展望
    • 相關/支持市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 技術格局
  • 定價模式分析
  • 法律規範
  • 產品平臺分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19影響分析

第4章美國病毒疫苗CDMO市場：類型評估與趨勢分析

  • 細分儀表板
  • 病毒疫苗CDMO市場：類型變化分析
  • 按類型，2021-2033年
  • 減毒疫苗
  • 去活化疫苗
  • DNA疫苗
  • 次單位疫苗

第5章美國病毒疫苗CDMO市場：服務評估與趨勢分析

  • 細分儀表板
  • 病毒疫苗CDMO市場：服務波動分析
  • 按服務分類，2021-2033 年
  • 配方和工藝開發
    • 上游開發
    • 下游開發
  • 分析測試
  • 灌裝和精加工服務
  • 包裝和標籤
  • 其他

第6章美國病毒疫苗CDMO市場：工作流程估算與趨勢分析

  • 細分儀表板
  • 病毒疫苗CDMO市場：工作流程變化分析
  • 按工作流程，2021-2033 年
  • 臨床
  • 商業

第7章美國病毒疫苗CDMO市場：最終用途估計與趨勢分析

  • 細分儀表板
  • 病毒疫苗 CDMO 市場：最終用途差異分析
  • 依最終用途，2021-2033 年
  • 生物製藥公司
  • 學術研究所
  • 其他

第8章 競爭態勢

  • 公司分類
    • 市場領導者
    • 新興企業
  • Company Market Assessment Analysis, 2024
  • 公司簡介
    • Lonza
    • Catalent, Inc.
    • Thermo Fisher Scientific, Inc.
    • Fujifilm Diosynth Biotechnologies
    • Samsung Biologics
    • Emergent BioSolutions
    • Recipharm AB.
    • Boehringer Ingelheim BioXcellence
    • Alcami Corporation
    • Vetter Pharma
Product Code: GVR-4-68040-624-4

U.S. Viral Vaccines CDMO Market Trends:

The U.S. viral vaccines CDMO market size was estimated at USD 750.2 million in 2024 and is projected to grow at a CAGR of 14.94% from 2025 to 2033. The growth is primarily attributed to strong government funding, advancements in vaccine technologies, and increasing demand for rapid, scalable production. Additionally, CDMOs with advanced capabilities such as single-use systems, lipid nanoparticle formulation, and fill-finish services are in high demand as pharmaceutical companies increasingly outsource to reduce costs and speed up timelines. Strategic partnerships, pandemic preparedness goals, and support from organizations like CEPI further the market growth.

The rising prevalence of viral diseases such as Respiratory Syncytial Virus (RSV), influenza, and monkeypox is accelerating demand for the U.S. viral vaccines CDMO market. Following pandemic-related trends, RSV surged significantly in 2022, resulting in hospitalizations among infants under six months, which increased sevenfold compared to pre-pandemic levels. Meanwhile, influenza test positivity in early 2025 rose to 18.7% across 44 states, along with rising hospitalizations and pediatric fatalities. At the same time, the monkeypox outbreak during 2022-2023 accounted for over 34,700 U.S. cases, prompting the administration of more than 1 million JYNNEOS vaccines. These surges have compelled public health agencies and vaccine developers to enhance manufacturing capacity, leading to contracts, process development, and infrastructure upgrades through CDMOs. This, in turn, supports market growth in the U.S.

The growth of the U.S. viral vaccines CDMO industry is significantly driven by public health emergencies and increasing demand for scalable, rapid vaccine production. Programs like Operation Warp Speed have catalyzed partnerships between the government and CDMOs, with over USD 10 billion in funding allocated to expand domestic manufacturing for COVID-19 and future outbreaks. This focus on pandemic readiness has led to long-term contracts through entities like BARDA, fostering consistent CDMO project pipelines. At the same time, pharmaceutical and biotech firms are increasingly outsourcing vaccine development and manufacturing to CDMOs to reduce upfront capital investments, accelerate time to market, and manage risks across complex viral platforms. Outsourcing also allows companies to concentrate on core R&D activities while leveraging CDMOs' regulatory expertise and GMP infrastructure. This strategic shift, particularly evident in viral-vectored and multivalent vaccine development, positions U.S.-based CDMOs as key enablers of national biosecurity and public-private preparedness, enhancing long-term market growth opportunities.

U.S. Viral Vaccines CDMO Market Report Segmentation

This report forecasts revenue growth country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. viral vaccines CDMO market report based on type, workflow, service, and end use:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Attenuated Vaccine
  • Inactivated Vaccine
  • DNA Vaccines
  • Subunit Vaccines
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical
  • Commercial
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Formulation & Process Development
    • Upstream Development
    • Downstream Development
  • Analytical Testing
  • Fill-Finish Services
  • Packaging & Labeling
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Biopharmaceutical Companies
  • Academic & Research Institutes
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Regulatory Framework
  • 3.6. Product Pipeline Analysis
  • 3.7. Industry Analysis Tools
    • 3.7.1. Porter's Five Forces Analysis
    • 3.7.2. PESTEL Analysis
    • 3.7.3. COVID-19 Impact Analysis

Chapter 4. U.S. Viral Vaccines CDMO Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Viral Vaccines CDMO Market: Type Movement Analysis
  • 4.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • 4.4. Attenuated Vaccine
    • 4.4.1. Attenuated Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Inactivated Vaccine
    • 4.5.1. Inactivated Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. DNA Vaccines
    • 4.6.1. DNA Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Subunit Vaccines
    • 4.7.1. Subunit Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Viral Vaccines CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Viral Vaccines CDMO Market; Service Movement Analysis
  • 5.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • 5.4. Formulation & Process Development
    • 5.4.1. Formulation & Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. Upstream Development
      • 5.4.2.1. Upstream Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Downstream Development
      • 5.4.3.1. Downstream development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Analytical Testing
    • 5.5.1. Analytical Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Fill-Finish Services
    • 5.6.1. Fill-Finish Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Packaging & Labeling
    • 5.7.1. Packaging & Labeling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Viral Vaccines CDMO Market: Workflow Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Viral Vaccines CDMO Market; Workflow Movement Analysis
  • 6.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • 6.4. Clinical
    • 6.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Commercial
    • 6.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Viral Vaccines CDMO Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Viral Vaccines CDMO Market; End Use Movement Analysis
  • 7.3. Viral Vaccines CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • 7.4. Biopharmaceutical Companies
    • 7.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Academic and Research Institutes
    • 7.5.1. Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Company Market Assessment Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Lonza
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Catalent, Inc.
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Thermo Fisher Scientific, Inc.
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Fujifilm Diosynth Biotechnologies
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Samsung Biologics
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Emergent BioSolutions
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Recipharm AB.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Boehringer Ingelheim BioXcellence
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Alcami Corporation
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Vetter Pharma
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Service benchmarking
      • 8.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 3 U.S. viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 4 U.S. viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 5 U.S. viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. Viral vaccines CDMO market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot 1
  • Fig. 14 Segment snapshot 2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Porter's five force analysis
  • Fig. 17 PESTEL analysis
  • Fig. 18 U.S. Viral vaccines CDMO Market: Type outlook key takeaways
  • Fig. 19 U.S. Viral vaccines CDMO Market: Type movement analysis
  • Fig. 20 Attenuated vaccine market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 DNA vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Subunit vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 U.S. viral vaccines CDMO Market: Services outlook key takeaways
  • Fig. 24 U.S. viral vaccines CDMO Market: Services movement analysis
  • Fig. 25 Formulation & process development market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Upstream development market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Downstream development market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Analytical testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Fill-finish services market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Packaging & labeling market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. viral vaccines CDMO Market: Workflow outlook key takeaways
  • Fig. 33 U.S. viral vaccines CDMO Market: Workflow movement analysis
  • Fig. 34 Clinical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Commercial market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Biopharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Academic and research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Strategic framework